Showing results (171-180 of 186) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2023
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II StudyHuiqiang Huang, Rong Tao, Siguo Hao, et al.
Biomarker Research|February 7, 2023
Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1-2 follicular lymphoma: a real-world multicenter studyJie Zha, Qinwei Chen, Jingjing Ye, et al.
Eclinicalmedicine|September 2, 2025
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 studyJunning Cao, Guangliang Chen, Lihua Qiu, et al.
Biomarker Research|January 3, 2025
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphomaJie Zha, Qinwei Chen, Wei Zhang, et al.
Haematologica|January 18, 2024
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumorsYuqin Song, Junning Cao, Qingyuan Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|August 21, 2007
Pyrimidine benzamide-based thrombopoietin receptor agonistsLawrence A Reiter, Chakrapani Subramanyam, Emilio J Mangual, et al.
Hematological Oncology|July 20, 2022
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trialYuankai Shi, Qingyuan Zhang, Xiaonan Hong, et al.
Blood|January 10, 2023
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trialYuqin Song, Hervé Tilly, Shinya Rai, et al.
Frontiers in Pharmacology|April 15, 2021
Antibiotic Use Among Hospitalized Children and Neonates in China: Results From Quarterly Point Prevalence Surveys in 2019Chu-Ning Wang, Jianning Tong, Bin Yi, et al.
The Lancet. Oncology|December 13, 2023
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Luis Malpica, Qingqing Cai, et al.
Pageof 19